Year All20242023202220212020201920182017201620152014 Abivax’s Covid-19 phase 2b/3 miR-AGE trial with ABX464 declared Research National Priority by the French government’s clinical trial council December 22, 2020 Read More Abivax to present at the 39th Annual J.P. Morgan Healthcare Conference ahead of major clinical milestones December 21, 2020 Read More Abivax establishes clinical, regulatory and manufacturing framework for ABX464 phase 3 program and potential commercialization in 2021 December 09, 2020 Read More Abivax 2021 Financial Communication Calendar December 03, 2020 Read More Abivax completes recruitment of ABX464 Phase 2b induction study in ulcerative colitis November 30, 2020 Read More Abivax receives “Best Technology Award” at the European Mediscience Awards 2020 November 16, 2020 Read More Abivax announces webcast and teleconference following recent oversubscribed capital increase of EUR 28m at market price November 02, 2020 Read More ABIVAX ANNOUNCES THE SUCCESS OF ITS OVERSUBSCRIBED CAPITAL INCREASE OF EUR 28M AT MARKET PRICE October 29, 2020 Read More Abivax secures EUR 15m non-dilutive financing from Kreos Capital October 13, 2020 Read More ABIVAX ANNOUNCES THE RELEASE OF ITS 2020 HALF-YEAR FINANCIAL REPORT September 30, 2020 Read More
Abivax’s Covid-19 phase 2b/3 miR-AGE trial with ABX464 declared Research National Priority by the French government’s clinical trial council December 22, 2020 Read More
Abivax to present at the 39th Annual J.P. Morgan Healthcare Conference ahead of major clinical milestones December 21, 2020 Read More
Abivax establishes clinical, regulatory and manufacturing framework for ABX464 phase 3 program and potential commercialization in 2021 December 09, 2020 Read More
Abivax completes recruitment of ABX464 Phase 2b induction study in ulcerative colitis November 30, 2020 Read More
Abivax receives “Best Technology Award” at the European Mediscience Awards 2020 November 16, 2020 Read More
Abivax announces webcast and teleconference following recent oversubscribed capital increase of EUR 28m at market price November 02, 2020 Read More
ABIVAX ANNOUNCES THE SUCCESS OF ITS OVERSUBSCRIBED CAPITAL INCREASE OF EUR 28M AT MARKET PRICE October 29, 2020 Read More
